Key result
Type 2 diabetes was associated with higher in-hospital mortality in STEMI patients (6.1% vs 3.5%), but this risk was no longer significant after adjusting for cardio-renal function (OR 1.03; P=0.89).
Why the study?
STEMI patients with type 2 DM have higher in-hospital mortality than those without, and it was hypothesized this disparity may stem from higher rates of cardiac and renal dysfunction.
Does type 2 diabetes mellitus increase in-hospital mortality in STEMI patients treated with primary angioplasty independently of baseline cardio-renal function?
Cohort (n=5,152)
Does type 2 diabetes mellitus increase in-hospital mortality in STEMI patients treated with primary angioplasty independently of baseline cardio-renal function?
Odds Ratio: 1.81 (95% CI 1.31–2.49)
Absolute Event Rate: 6.1% vs 3.5%
p-value: p=<0.001
The increased in-hospital mortality and morbidity observed in STEMI patients with type 2 diabetes is primarily driven by underlying cardiac and renal dysfunction rather than diabetes itself.
Cardio-renal status explains excess STEMI mortality with diabetes; leaves open independent effects on longer-term outcomes.
OBJECTIVE ST-segment elevation myocardial infarction (STEMI) patients with type 2 diabetes mellitus (DM) have higher in-hospital mortality than those without. Since cardiac and renal functions are the main variables associated with outcome in STEMI, we hypothesized that this prognostic disparity may depend on a higher rate of cardiac and renal dysfunction in DM patients. RESEARCH DESIGN AND METHODS We retrospectively analyzed 5,152 STEMI patients treated with primary angioplasty. Left ventricular ejection fraction (LVEF) and estimated glomerular filtration rate (eGFR) were evaluated at hospital admission. The primary end point was in-hospital mortality. A composite of in-hospital mortality, cardiogenic shock, and acute kidney injury was the secondary end point. RESULTS There were 879 patients (17%) with DM. The incidence of LVEF ≤40% (30% vs. 22%), eGFR ≤60 mL/min/1.73 m2 (27% vs. 18%), or both (12% vs. 6%) was higher (P < 0.001 for all comparisons) in DM patients. In-hospital mortality was higher in DM patients than in non-DM patients (6.1% vs. 3.5%; P = 0.002), with an unadjusted odds ratio (OR) of 1.81 (95% CI 1.31–2.49; P < 0.001). However, DM was no longer associated with an increased mortality risk after adjustment for cardiac and renal function (OR 1.03, 95% CI 0.68–1.56; P = 0.89). A similar behavior was observed for the secondary end point, with an unadjusted OR for DM of 1.52 (95% CI 1.25–1.85; P < 0.001) and an OR after adjustment for cardiac and renal function of 1.07 (95% CI 0.85–1.36; P = 0.53). CONCLUSIONS The study indicates that the increased in-hospital mortality and morbidity of DM patients with STEMI is mainly driven by their underlying cardio-renal dysfunction.
No takes yet. Share an insight, caveat, or question.
Marenzi et al. (2019) conducted a cohort in ST-segment elevation myocardial infarction (STEMI) (n=5,152). Type 2 diabetes mellitus vs. Without type 2 diabetes mellitus was evaluated on In-hospital mortality (OR 1.81, 95% CI 1.31-2.49, p=<0.001). Type 2 diabetes was associated with higher in-hospital mortality in STEMI patients (6.1% vs 3.5%), but this risk was no longer significant after adjusting for cardio-renal function (OR 1.03; P=0.89).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: